Order Article Reprints

Juszczyk E, Kisło K, Żero P, Tratkiewicz E, Wieczorek M, Paszkowska J, Banach G, Wiater M, Hoc D, Garbacz G, et al. Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial. Pharmaceutics. 2021; 13(6):804. https://doi.org/10.3390/pharmaceutics13060804

Juszczyk, Ewelina, Kamil Kisło, Paweł Żero, Ewa Tratkiewicz, Maciej Wieczorek, Jadwiga Paszkowska, Grzegorz Banach, Marcela Wiater, Dagmara Hoc, Grzegorz Garbacz, and et al. 2021. "Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial" Pharmaceutics 13, no. 6: 804. https://doi.org/10.3390/pharmaceutics13060804

Juszczyk, E., Kisło, K., Żero, P., Tratkiewicz, E., Wieczorek, M., Paszkowska, J., Banach, G., Wiater, M., Hoc, D., Garbacz, G., Sczodrok, J., & Danielak, D. (2021). Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial. Pharmaceutics, 13(6), 804. https://doi.org/10.3390/pharmaceutics13060804